2-氟-3-甲基苯硼酸 | 762287-58-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-3-甲基苯硼酸
• 英文名称: (2-fluoro-3-methylphenyl)boronic acid
• 英文别名: 2-Fluoro-3-methylphenylboronic acid
• CAS: 762287-58-1
• 化学式: C₇H₈BFO₂
• 分子量: 153.949
• InChiKey: VEHQHYJZLSODOU-UHFFFAOYSA-N

物化性质

• 熔点：
  160-161℃
• 沸点：
  291℃
• 密度：
  1.20
• 闪点：
  130℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.19
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-3-methylphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-3-methylphenylboronic acid
CAS number: 762287-58-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8BFO2
Molecular weight: 153.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-3-甲基苯硼酸 在 硝酸 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 16.0h， 以87%的产率得到2-氟-3-硝基甲苯
  参考文献：
  名称：

  用发烟硝酸对芳基硼酸进行 Ipso 硝化

  摘要：

  使用发烟硝酸作为硝化剂，已经开发了芳基硼酸衍生物的原位硝化。这种简便的程序提供了对各种芳族硝基化合物的有效和化学选择性访问。虽然文献中已经报道了几种活化剂和硝基源可用于这种综合有用的转化，但本报告表明这些过程可能会产生一种常见的活性试剂无水 HNO 3。动力学和机理研究表明，HNO 3中的反应级数大于2，表明• NO 2自由基是活性物质。

  DOI：

  10.1021/acs.joc.1c00886
• 作为产物：
  描述：

  2-氟甲苯 在 正丁基锂 、 potassium tert-butylate 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 2.0h， 以48%的产率得到2-氟-3-甲基苯硼酸
  参考文献：
  名称：

  General method for the synthesis of substituted phenanthridin-6(5H)-ones using a KOH-mediated anionic ring closure as the key step

  摘要：

  Substituted phenanthridin-6(5H)-ones were obtained in a two-step procedure involving a Suzuki cross-coupling reaction followed by a KOH-mediated anionic ring closure. The influence of the nature and the position of the substituents on the cyclization step were studied. This methodology offers a general and practical route to diversely substituted phenanthridin-6(5H)-ones. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.05.014

文献信息

• Discovery of Antimetastatic Chiral Ionone Alkaloid Derivatives Targeting HIF‐1α/VEGF/VEGFR2 Pathway
  作者：Jing‐Jing Liu、Xin‐Yao Liu、Jiang‐Ping Nie、Mei‐Qi Jia、Yang Yu、Nan Qin、Hong‐Quan Duan

  DOI：10.1002/cmdc.202100072

  日期：——

  Novel chiral ionone alkaloid derivatives were synthesized and their antimetastatic effects were evaluated in human breast cancer cells using chemotaxis assay. Compared with positive control LY294002, a PI3 K inhibitor, derivatives 10 a, 11 a, 11 c, 11 g, 11 j, 11 k and 11 w exhibited significant inhibitory effects against cancer cell migration. Especially, the IC50 for compound 11 g was as low as 0

  合成了新型手性紫罗兰酮生物碱衍生物，并使用趋化性测定在人乳腺癌细胞中评估了它们的抗转移作用。与阳性对照 LY294002 相比，PI3 K 抑制剂衍生物 10a 、11a、11c、11g、11j、11k和11w对癌细胞迁移具有显着的抑制作用。特别是化合物11 g的IC 50低至0.035±0.004 μM。对化合物11 g的进一步研究表明，它对 MDA-MB-231 细胞的粘附、迁移和侵袭具有抑制作用。11g抗肿瘤转移作用的机制可能是通过抑制 HIF-1α/VEGF/VEGFR2/Akt 通路，从而抑制下游信号分子，包括 Akt1/mTOR/p70S6K 和 Akt2/PKCζ/整合素 β1 通路。综上所述，手性紫罗兰酮生物碱衍生物11 g具有开发成为乳腺癌抗肿瘤转移剂的潜力。
• PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20120122899A1

  公开（公告）日：2012-05-17

  The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及哌啶酮羧酰胺吖啶衍生物，它们是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这类疾病中使用这些化合物和组合物。
• 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors
  申请人：Arrien Pharmaceuticals LLC

  公开号：US20140315909A1

  公开（公告）日：2014-10-23

  The present invention relates to compounds described by Formula I: salts thereof, their synthesis, and their use as ITK and JAK3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, Crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention.

  本发明涉及由式I描述的化合物： 其盐，它们的合成，以及它们作为ITK和JAK3抑制剂的用途，包括这些化合物以及使用这些化合物治疗各种疾病和/或疾病的方法，这些疾病与异常细胞生长有关，如自身免疫、炎症、类风湿关节炎、系统性红斑狼疮、动脉粥样硬化、溃疡性结肠炎、银屑病性关节炎、银屑病、克罗恩病、代谢和癌症疾病。本发明还提供包括本发明化合物的药学上可接受的组合物以及使用这些组合物的方法和制备本发明化合物的方法。
• BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
  申请人：Incyte Corporation

  公开号：US20210106588A1

  公开（公告）日：2021-04-15

  The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

  这项发明涉及双环杂环化合物及其药物组合物，这些化合物是FGFR酶的抑制剂，可用于治疗与FGFR相关的疾病，如癌症。
• 一种氨基噻唑类衍生物
  申请人：重庆大学

  公开号：CN107266388A

  公开（公告）日：2017-10-20

  本发明涉及一类氨基噻唑类杂环衍生物，其制备方法，以及在制备治疗或预防进行性认知障碍和/或记忆力缺失疾病的药物中的用途。